The National Chamber of Innovative Health of Uzbekistan and the Robert Koch Institute (Germany) will cooperate in the preparation of clinical protocols for COVID-19 treatment, based on evidence-based medicine, the press service of the Chamber informs.
“This is particularly important now when the use of certain drugs must be reconsidered based on international experience, accumulated during the months of the pandemic, and in the recommendations of the World Health Organization,” the report notes.
This viewpoint was supported during a videoconference in early September held at the initiative of the Robert Koch Institute for specialists of the National Chamber. The online discussion was part of a series of partnership meetings between the sides which started on May 13.
There is a network of infectious diseases clinics in Germany working under the auspices of the R. Koch Institute. The National Chamber of Uzbekistan has been invited to cooperate with the network, which should facilitate the productive work on the provisional clinical guidelines for COVID-19 treatment, considering the experience of German specialists, as well as their wide range of professional contacts. The recommendations accumulated by the institute during the pandemic are also reflected in WHO documents.
“Today, the parties emphasized the need for an exchange of experience in order to adopt clinical guidelines and protocols, which are best for the patients. Cooperation in this direction is expected to be continued,” the press service added.
Development of modern clinical manuals and protocols, quality standards for diagnosis and treatment, as well as logistics standards, monitoring their timely introduction is one of the main tasks of the National Chamber of Innovative Health Care.